Volume 13, Issue 2, April 2023

Development and Validation for Estimation of Anti-Viral Agent Molnupiravir in Bulk Form and Marketed Pharmaceutical Tablet Dosage Form (Research Article)

Author(s): Gangadhari Harika and Gade Sammaiah
Abstract: A new, simple, rapid, precise, accurate and reproducible RP-HPLC method for estimation of Molnupiravir in bulk form and marketed formulation. Separation of Molnupiravir was successfully achieved on a Develosil ODS HG-5 RP C18, 5μm, 15cmx4.6mm i.e., column in an isocratic mode of separation utilizing Methanol: Phosphate buffer (0.02M, pH-3.6) in the ratio of 45:55% v/v at a flow rate of 1.0 mL/min and the detection was carried out at 255nm. The method was validated according to ICH guidelines for linearity, sensitivity, accuracy, precision, specificity and robustness. The response was found to be linear in the drug concentration range of 12-28mcg/mL for Molnupiravir. The correlation coefficient was found to be 0.9995 for Molnupiravir. The LOD and LOQ for Molnupiravir were found to be 5.004μg/mL and 15.164μg/mL respectively. The proposed method was found to be good percentage recovery for Molnupiravir, which indicates that the proposed method is highly accurate. The specificity of the method shows good correlation between retention times of standard solution with the sample solution. Therefore, the proposed method specifically determines the analyte in the sample without interference from excipients of pharmaceutical dosage forms.
PAGES: 190-200  |  42 VIEWS  90 DOWNLOADS

How To Cite this Article:

Gangadhari Harika and Gade Sammaiah. Development and Validation for Estimation of Anti-Viral Agent Molnupiravir in Bulk Form and Marketed Pharmaceutical Tablet Dosage Form (Research Article). 2023; 13(2): 190-200.